Pediatric Rheumatology
Tools
Share this article

Email updates

Keep up to date with the latest news and articles from Pediatric Rheumatology and BioMed Central.

This article is part of the supplement: 15th Paediatric Rheumatology European Society (PreS) Congress

Open Access Poster presentation

Diagnostic value and clinical significance of antibodies against a modified citrullinated vimentin (anti-MCV) in patients with early juvenile arthritis

SO Salugina1*, ES Fedorov1, EN Alexandrova1, AA Novikov1, MV Cherkasova1, AA Baranov2, YA Valogina2, TN Nikolaeva2 and NA Zubova2

  • * Corresponding author: SO Salugina

Author Affiliations

1 Institute of Rheumatology RAMS, Moscow, Russian Federation

2 Department of Clinical Pathology, Yaroslavl Medical Academy, Yaroslavl, Russian Federation

For all author emails, please log on.

Pediatric Rheumatology 2008, 6(Suppl 1):P9 doi:10.1186/1546-0096-6-S1-P9


The electronic version of this article is the complete one and can be found online at: http://www.ped-rheum.com/content/6/S1/P9


Published:15 September 2008

© 2008 Salugina et al; licensee BioMed Central Ltd.

Objective

To investigate the diagnostic value and clinical significance of anti-MCV in pts with early JA.

Patients and methods: 85 pts were included in the study (M/F = 36/49) in the age of 1,5–16 years (mean 8.7 ± 4.9 years). Systemic JA – 10 pts (11.8%), poly – 37 (43.5%), oligo-38 (44.7%). Duration of disease was < 6 months. We studied also 54 pts with early RA, 28 pts with undifferentiated arthritis (UA) and 14 healthy children. Anti-MCV was measured in serum by enzyme-linked immunosorbent assay (ELISA) using the cut off value of 25 U/ml. IgM RF and hsCRP-by laser-nephelometry assay on BN-100 analyser.

Results

Anti-MCV levels were elevated in 23 (27.1%) pts with early JA, in systemic – 2 (20%), poly – 11(29.7%), oligo-10 (26.3%). In pts with RF positive JA – 5 (100%), in RF negative pts- 7(17.1%) (p < 0.001). In the control groups: 34/54 (62.9%) adults with early RA (p < 0,001), 14/28 (50%) with UA (p < 0.05), none of the healthy children showed anti-MCV positivity. The median anti-MCV level in JA was 16.8 U/ml (IR: 11.5–26.4), in RF+ pts (M-834.9; IR 539.3–1149.3 U/ml) was higher than in RF-pts (M-14.5; IR:5.7–22.0 U/ml) (p < 0.001). Anti-MCV correlated with parameters of disease activity (hs CRP, ESR), with RF and anti-CCP positivity. Anti-MCV were not associated with ANA.

Conclusion

Determination of anti-MCV levels especially together with RF and anti-CCP in pts with early JA can indicate evolution JRA similar RA in adults. Anti-MCV levels correlated with common parameters of inflammation and acute phase response and may be useful to monitor disease activity.